As Toleranzia's current CFO Thomas Pålsson is temporarily unable to act as CFO for health reasons and needs to undergo the necessary medical treatment before he can return to work, the company has today contracted Ann-Sofie Taube to maintain the position as Toleranzia's CFO on an interim basis until further notice.
 
Ann-Sofie Taube has more than 30 years of experience as a CFO, business controller and financial advisor in various businesses and industries and thus solid experience of financial management and business development. Previous clients include Acosense AB, Aluwave AB, Yara Marine Technologies, and mentoring assignments for Connect Väst regarding ScaleUp companies. Ann-Sofie's solid background includes studies in economics and organizational psychology at the University of Gothenburg.
 
"We are very pleased to be able to welcome Ann-Sofie Taube to the position of CFO at Toleranzia on short notice. With her background and experience, she will quickly get into the business during the temporary absence of our CFO. At the same time, we hope that Thomas' medical treatment proceeds quickly and efficiently, and that we see him back in service soon", comments Charlotte Fribert, CEO of Toleranzia.
 
 
For further information, please contact
Charlotte Fribert - CEO, Toleranzia AB
Tel: +46 763 19 98 98
E-mail: charlotte.fribert@toleranzia.com
 
About Toleranzia AB (publ)
Toleranzia AB (publ) develops medicines that harness the power of the immune system to treat rare autoimmune diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, just reduce symptoms. They have the potential to be the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company's Certified Adviser.